Home > Publications Database > Microglia synapse interaction precedes synapse elimination in mouse models of AD > print

001     145342
005     20230915101331.0
037 _ _ |a DZNE-2020-00698
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Chamoun, Miriam
|0 P:(DE-2719)2813057
|b 0
|e First author
|u dzne
111 2 _ |a GLIA Edinburgh 2017
|c Edinburgh
|d 2017-07-08 - 2017-07-11
|w Scotland
245 _ _ |a Microglia synapse interaction precedes synapse elimination in mouse models of AD
260 _ _ |c 2017
336 7 _ |a Abstract
|b abstract
|m abstract
|0 PUB:(DE-HGF)1
|s 1596109063_11286
|2 PUB:(DE-HGF)
336 7 _ |a Conference Paper
|0 33
|2 EndNote
336 7 _ |a INPROCEEDINGS
|2 BibTeX
336 7 _ |a conferenceObject
|2 DRIVER
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|m journal
336 7 _ |a Output Types/Conference Abstract
|2 DataCite
336 7 _ |a OTHER
|2 ORCID
520 _ _ |a Microglia are actively surveying the brain parenchyma by protracting and retracting their fine processes. They physically interact with neurons and their synapses and have been shown to influence the morphology of dendritic spines dependent on the contact rate under normal physiological conditions. Under neurodegenerative disease conditions like Alzheimer¶s disease (AD), microglia mediate early synapse loss via the complement system or neuron loss dependent on the fractalkine receptor (CX3CR1). It remains unresolved whether microglia contribute to synapse loss during late disease stages, whether that changes contact rates or involves neuron microglia communication via the CX3CR1 receptor. To address these open questions, we carried out time-lapse two-photon in vivo imaging in the hippocampus and cortex of two different mouse models of AD, the APP/PS1 and the 3xTg-AD model. We analyzed dendritic spine loss in relation to microglia contact rates of dendritic spines and with respect to CX3CR1-deficiency under advanced AD-like conditions. We found increased turnover and loss of dendritic spines under AD-like conditions. Furthermore, spine loss in proximity to Aȕ-plaques was ameliorated in CX3CR1-deficient APP/PS1 mice. Surprisingly, the microglia contact rates of dendritic spines before elimination were significantly reduced dependent on CX3CR1-deficiency. Reduced microglia contact rates dependent on CX3CR1-deficiency were consistently found in APP/PS1 and 3xTg-AD mice similarly in the cortex and hippocampus. These data indicate that microglia mediate synapse loss via elevated physical synapse interactions dependent on the CX3CR1 receptor under advanced AD-like conditions.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
700 1 _ |a Nebeling, Felix
|0 P:(DE-2719)2811414
|b 1
|u dzne
700 1 _ |a Schneider, J
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Steffen, Julia
|0 P:(DE-2719)2810279
|b 3
|u dzne
700 1 _ |a Gu, Ligang
|0 P:(DE-2719)2810398
|b 4
|u dzne
700 1 _ |a Fuhrmann, Martin
|0 P:(DE-2719)2679991
|b 5
|e Last author
|u dzne
773 _ _ |0 PERI:(DE-600)1474828-9
|n S1
|p E290
|t Glia
|v 65
|y 2017
|x 0894-1491
856 4 _ |u https://onlinelibrary.wiley.com/doi/epdf/10.1002/glia.23157
909 C O |o oai:pub.dzne.de:145342
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2813057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2811414
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810279
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2679991
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|2 G:(DE-HGF)POF3-300
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2017
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-02-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-02-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-02-26
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-08
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-08
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GLIA : 2021
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b GLIA : 2021
|d 2022-11-08
920 1 _ |0 I:(DE-2719)1011004
|k AG Fuhrmann
|l Neuroimmunology and Imaging
|x 0
920 1 _ |0 I:(DE-2719)1310003
|k AG Müller
|l Neuroprotection
|x 1
980 _ _ |a abstract
980 _ _ |a VDB
980 _ _ |a journal
980 _ _ |a I:(DE-2719)1011004
980 _ _ |a I:(DE-2719)1310003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21